Drug
IBI363 + chemotherapy
IBI363 + chemotherapy is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
NCT07408635
not_yet_recruitingphase_1
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT07342725
recruitingphase_2
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
NCT07325630
recruitingphase_1
A Study of IBI363 in Subjects With Advanced Malignancies
NCT06468098
Clinical Trials (4)
Showing 4 of 4 trials
NCT07408635Phase 2
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
NCT07342725Phase 1
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT07325630Phase 2
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
NCT06468098Phase 1
A Study of IBI363 in Subjects With Advanced Malignancies
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4